STROMAL EXPRESSION OF CD10 IN BREAST CANCER- A NEW PROGNOSTIC MARKER

Published: 17 November 2017| Version 1 | DOI: 10.17632/tjg79nwg9s.1
Contributors:
maria kamal,
Roobina Khan,
Veena Maheshwari,
S. Hasan Harris,
Mohsin Aijaz

Description

• Breast cancer is the most common cause of cancer death among women worldwide and is essential to diagnose and treatment early. • Novel stromal markers are now emerging to aid in predicting the prognosis and treatment of malignant breast lesions. • CD10 is a membrane-bound metalloprotease that cleaves protein components of extracellular matrix, playing a role in tumor progression. • CD10 is expressed on the surface of a variety of normal cells including breast myoepithelial cells. • Stromal expression of CD10 is associated with poor prognosis in breast cancer. • Routine CD10 staining may help in planning the treatment for breast cancer patients. Also, CD10 can be used as a target for the development of novel therapies.

Files

Categories

Pathology of Breast Cancer

License